Serum noggin levels are not correlated with bone density or fractures and are not affected by treatment for osteoporosis

Noggin is a protein involved in the development of many body tissues, including nerve tissue, muscles, and bones. Noggin inhibits bone morphogenetic proteins which are molecules that exert a positive effect on bone formation and thus bone mass. Therefore, noggin is expected to have a negative impact on bone formation.

However, circulating noggin levels had not been evaluated in women with postmenopausal osteoporosis. Furthermore, there was no information regarding the effect of anti-osteoporotic therapy on noggin levels. To address these issues, the ECTS Academy member Athanasios Anastasilakis and colleagues conducted a study to evaluate the effect of denosumab, the most potent currently available antiresorptive treatment for osteoporosis, and teriparatide, the only osteoanabolic currently available in the European Union, on noggin concentrations. In this study, which was published in the Journal of Musculoskeletal and Neuronal Interactions, authors found that noggin levels did not differ between women with vertebral or non-vertebral fractures compared with those without fractures and remained unchanged after either denosumab or teriparatide treatment. Noggin levels were not correlated with age or bone mineral density but were correlated with bone formation marker P1NP at 12 months of treatment.

See the original article here: